Набор скоро начнётся NCT07336641

LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice

— Наблюдательное Psoriasis Atopic Dermatitis Vitiligo Alopecia Areata

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: Conventional Systemic Therapies, Biologic Therapies.
Кому может быть актуально: Состояния в реестре: Psoriasis, Atopic Dermatitis, Vitiligo, Alopecia Areata. Базовые параметры: от 12 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: Италия
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

LANDSCAPE - Demographic Characteristics and Treatment Profiles of Patients Affected by Inflammatory Skin Diseases (Psoriasis, Atopic Dermatitis, Alopecia Areata, Vitiligo, Hidradenitis Suppurativa) in Italian Clinical Practice

Обзор

This multicenter retrospective observational registry study will collect existing clinical data from Italian centers to describe epidemiology, treatment patterns, clinical evolution, safety, and comorbidities in patients aged 12 years and older with psoriasis, atopic dermatitis, vitiligo, alopecia areata, or hidradenitis suppurativa.

Подробное описание

LANDSCAPE is a non-interventional, multicenter, retrospective disease registry based on routinely collected clinical data (electronic health records and available medical documentation) from participating Italian centers. Data will cover the period January 2016 to December 2025. The registry will support real-world evaluation of treatment patterns, effectiveness and safety outcomes, disease severity scores, persistence/switching, and associated comorbidities across psoriasis, atopic dermatitis, vitiligo, alopecia areata, and hidradenitis suppurativa. Data will be pseudonymized prior to entry into the EDC system. Patients who exercise the opt-out right will not be included.

Вмешательства

Препарат Conventional Systemic Therapies
Retrospective observation of conventional systemic treatments prescribed in routine clinical practice, including but not limited to methotrexate, cyclosporine, acitretin, and other conventional agents. No drugs are administered as part of this study; treatment data are collected from existing medical records.
Препарат Biologic Therapies
Retrospective observation of biologic treatments prescribed in routine clinical practice, including but not limited to TNF-α inhibitors, IL-17 inhibitors, IL-23 inhibitors, IL-4/IL-13 inhibitors, and JAK inhibitors. No drugs are administered as part of this study; treatment data are collected from existing medical records.

Первичные конечные точки

Patient Distribution by Disease Type [Срок оценки: January 2016 to December 2025]
Age at Treatment Initiation [Срок оценки: January 2016 to December 2025]
Sex Distribution [Срок оценки: January 2016 to December 2025]

Вторичные конечные точки (3)

Treatment Patterns and Therapeutic Sequences [Срок оценки: January 2016 to December 2025]
Disease Severity Assessment Over Time [Срок оценки: January 2016 to December 2025]
Treatment Persistence and Drug Survival [Срок оценки: January 2016 to December 2025]

Критерии участия

Критерии включения

Documented diagnosis of psoriasis, atopic dermatitis, vitiligo, alopecia areata, or hidradenitis suppurativa.
Age 12 years or older at the first recorded visit.
Eligible for or treated with systemic therapies.
At least one documented visit during January 2016 to December 2025.
No opt-out exercised.